PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of chronic myelogenous leukemia confirmed by bone marrow biopsy
• * Chronic, accelerated, or blastic phase disease
• May have T315I mutation in BCR-ABL kinase
• Relapsed after prior imatinib mesylate or c-ABL therapy
• No CNS leukemia
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Blood pressure ≤ 140/90 mm Hg (with or without hypertension treatment for ≥ 1 week)
• Transaminases ≤ 2.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• Creatinine ≤ 1.5 times ULN
• No known history of HIV infection
• No active uncontrolled infection
• No grade 3 or 4 bleeding
• LVEF ≥ 45% by MUGA or ≥ 40% by transthoracic echocardiography
• No medical or psychiatric condition or laboratory abnormalities that would limit study compliance or increase risk during study participation
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 90 (female) or 180 (male) days after completion of study treatment
• No significant cardiovascular disease (i.e., uncontrolled arrhythmias or unstable angina) within the past 6 months
• No major thromboembolic event within the past 6 months, including any of the following:
• * Myocardial infarction
• * Stroke
• * Transient ischemic attack
• * Pulmonary embolism
• * Noncatheter-related deep-vein thrombosis
• PRIOR CONCURRENT THERAPY:
• Recovered from all acute toxic effects (excluding alopecia) of prior therapy
• More than 2 weeks since prior chemoimmunotherapy
• * Hydroxyurea must be discontinued 1 day prior to study therapy
• More than 4 weeks since prior major surgery
• No other concurrent approved or investigational anticancer treatment, including chemotherapy, biologic response modifiers, hormones, or immunotherapy
• No other concurrent investigational drugs
• No concurrent participation in another treatment clinical trial